Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
AVXL Stock Chart & Stats
$8.10
-$1.39(-10.33%)
At close: 4:00 PM EST
$8.10
-$1.39(-10.33%)
Day’s Range― - ―
52-Week Range$5.62 - $14.44
Previous CloseN/A
Volume1.46M
Average Volume (3M)1.23M
Market Cap
$695.74M
Enterprise Value$686.05M
Total Cash (Recent Filing)$101.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Dec 22, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding85,893,840
10 Day Avg. Volume1,066,472
30 Day Avg. Volume1,228,003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.63
Forecast
1Y Price Target
$42.00Price Target Upside418.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Alzheimer's Disease ResearchNew blarcamesine clinical data underscore potential applicability in stabilizing cognitive function in early Alzheimer's disease.
Regulatory ApprovalPositive CHMP commentary could have a huge upside to the current stock price and could have a positive readthrough with other non-US regulatory bodies.
Schizophrenia TreatmentAnavex recently reported positive top-line results from its placebo-controlled Phase 2 study evaluating ANAVEX3-71 for treatment of schizophrenia in adults on stable antipsychotic medication.
Bears Say
Clinical Data UncertaintyPhase 2b/3 and open-label extension data are confusing due to Covid disruptions, leading to uncertainty if the cohort size is large enough to receive full approval.
Financial PerformanceThe F3Q25 net loss of $13.2M, or $0.16 per share, was moderately wider than the forecast for a net loss of $0.13 per share.
Stock Market SentimentThe short percentage of float has held steady at approximately 30% for over 6 months, indicating significant bearish sentiment in the market.
Anavex Life Sciences News
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $5.62 and its highest was $14.44 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $695.74M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Dec 22, 2025 which is in 54 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Aug 12, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.018.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 85,893,840 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -5.022%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (418.52% Upside)
$42.00 (418.52% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 75%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
-43.63%
Trailing 12-Months
Asset Growth
-27.67%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases. The company is primarily focused on developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative and neurodevelopmental disorders. Anavex's lead compound, ANAVEX2-73 (blarcamesine), is being studied for its potential to modify disease progression and improve symptoms in these conditions.
AVXL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong ongoing development and financial health, but also challenges in administrative costs and net losses. The company's advancements in Alzheimer's treatment and cash flow are positive, but operational costs and delays in Parkinson's study present concerns.View all AVXL earnings summariesAVXL Stock 12 Month Forecast
Average Price Target
$42.00
▲(418.52% Upside)
Technical Analysis
Vir Biotechnology
―
Nurix Therapeutics
―
AbCellera Biologics
―
Day One Biopharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.36% Insiders
8.68% Mutual Funds
0.25% Other Institutional Investors
75.21% Public Companies and
Individual Investors